Market Movers: Pharma Giants Battle, Geopolitical Tensions Rise, and Energy Sector Expands
Key Takeaways Eli Lilly (LLY) has bolstered its position in the competitive obesity and cardiometabolic drug market, signing a US$1.3 […]
High-Stakes Summit Underway as Trump Expresses Optimism, Market Confidence
Key Takeaways President Trump has expressed optimism regarding his meeting with Russian President Vladimir Putin in Alaska, stating that he
Mixed Signals on Wall Street as Dow Hits Record, Tech Stumbles in Afternoon Trading
U.S. equity markets presented a mixed picture in afternoon trading on Friday, August 15, 2025, as investors navigated a landscape
Microsoft Forges Prediction Market Alliance; Oil Prices Ease on Peace Hopes
Key Takeaways Microsoft's (MSFT) gaming division, including Activision and its flagship Call of Duty franchise, has reportedly partnered with prediction
Energy Markets Stable as Rig Count Holds; WEF Clears Schwab
Key Takeaways The U.S. total rig count remained steady at 539, with oil rigs seeing a slight increase while gas
Stock Market Today: Dow Hits Record High as UnitedHealth Soars on Buffett Stake
Midday Market Update: Mixed Performance as S&P 500 and Nasdaq Pull Back Major U.S. stock indexes showed mixed performance in
Federal Reserve Shifts Crypto Oversight, ChatGPT Mobile Revenue Hits $2 Billion, and Trump Issues Warning Ahead of Putin Summit
Key Takeaways The Federal Reserve is ending its specialized "novel activities supervision program," integrating oversight of banks' crypto and fintech
Market Volatility Surges as CoreWeave Trades Stir Speculation, Apple Faces Tariff Hit, and Geopolitical Tensions Mount
Key Takeaways CoreWeave shares experienced multiple large block trades, with 11 million shares placed by Goldman Sachs, JPMorgan, and Morgan
Midday Momentum: Tech Leads Market Rally on Strong AI Outlook and Economic Optimism
The U.S. stock market is demonstrating robust upward momentum in midday trading on Friday, August 15, 2025, with major indexes
Market Movers: Pfizer’s Sickle Cell Drug Fails Phase 3, Lukoil Refinery Halts, BP Gains on Takeover Buzz
Key Takeaways Pfizer's (PFE) experimental sickle cell disease drug, Inclacumab (also known as Thrive-131), failed to achieve its primary endpoint